Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8481796 | 0.83 | CYP11B1 (0.40) | CYP11B1CYP11B2HDAC3HDAC6HSP90AA1 | |
| SCHEMBL9239487 | 0.82 | CYP11B1 (0.37) | CYP11B1CYP11B2HDAC3HDAC6HSP90AA1 | |
| SCHEMBL6613495 | 0.82 | HDAC3 (0.40) | CYP11B1CYP11B2HDAC3HDAC6CYP2C19 | |
| SCHEMBL28067941 | 0.81 | CYP11B1 (0.42) | CYP11B1CYP11B2HDAC3HDAC6HSP90AA1 | |
| SCHEMBL27089283 | 0.81 | SMN1; SMN2 (0.36) | CYP11B1CYP11B2HDAC3HDAC6MEN1 | |
| SCHEMBL17009956 | 0.81 | HDAC3 (0.36) | CYP11B1CYP11B2HDAC3HDAC6HSP90AA1 | |
| SCHEMBL25307807 | 0.80 | CYP11B1 (0.38) | CYP11B1CYP11B2HDAC3HDAC6NR1I2 | |
| SCHEMBL27579878 | 0.80 | CYP11B1 (0.38) | CYP11B1CYP11B2HDAC3HDAC6HSP90AA1 | |
| SCHEMBL9234834 | 0.80 | HDAC3 (0.37) | CYP11B1CYP11B2HDAC3HDAC6HSP90AA1 | |
| SCHEMBL3516047 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2HDAC3HDAC6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190317040-A1 | DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-17 | — | — | US | disclosed |
| US-10442771-B2 | Trans-base tunnel reader for sequencing | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-10330632-B2 | Devices and methods for target molecule characterization | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170204066-A1 | NANOPORE BASED SEQUENCER | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-07-20 | — | — | US | disclosed |
| US-9593372-B2 | Nanopore based sequencer | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9395352-B2 | Devices and methods for target molecule characterization | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-07-19 | — | — | US | disclosed |
| US-9115122-B2 | Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150211059-A1 | TRANS-BASE TUNNEL READER FOR SEQUENCING | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2015-07-30 | — | — | US | disclosed |
| US-8968540-B2 | Trans-base tunnel reader for sequencing | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8961757-B2 | Nanopore and carbon nanotube based DNA sequencer | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| CN-1856475-A | Isoquinoline potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1667979-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030130-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6384061-B1 | HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS | LG CHEMICAL LTD. (KR) | 2002-05-07 | — | — | US | disclosed |
| EP-1000036-A1 | HYDANTOIN DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE | LG CHEMICAL LIMITED (KR) | 2000-05-17 | — | — | EP | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| WO-1999005117-A1 | HYDANTOIN DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE | LG CHEMICAL LTD. (KR) | 1999-02-04 | — | — | WO | disclosed |
| EP-0675112-A1 | Imidazole-containing inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204066-A1 | NANOPORE BASED SEQUENCER | DNMT3A, DNTT, TELO2 | CYP11B1 2318/4885CYP11B2 2092/4885HDAC3 4492/4885 |
| US-10442771-B2 | Trans-base tunnel reader for sequencing | DNTT, TRDMT1, TELO2 | CYP11B1 1094/4885CYP11B2 1175/4885HDAC3 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.